Clinical Commentary| Volume 15, ISSUE 6, P625-628, December 2017

Prostate Cancer Screening in a New Era of Genetics


      Men who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks. Although clinically important, there is lack of specific guidance regarding management strategies for men at increased risk owing to germline mutation status or family history of aggressive prostate cancer. We review prostate cancer genetic risk factors and the ongoing IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) screening study. Pending results of IMPACT and unified guidelines, there are areas of uncertainty and need for further study. Ongoing and future research will be critical for optimizing prostate cancer screening approaches for men at the highest risk for aggressive prostate cancer. In the interim, we propose a practical approach to prostate cancer screening for men with a germline mutation in a known/suspected moderate to high-penetrance cancer predisposition gene (eg, BRCA1/2), and/or men with a first- or second-degree relative with metastatic prostate cancer (regardless of genetic testing): baseline prostate-specific antigen and digital rectal exam by experienced providers at age 40 years or 5 years earlier than age of diagnosis of the youngest first- or second-degree relative with metastatic prostate cancer, whichever is earlier. Then, based on age, digital rectal exam, and prostate-specific antigen, we suggest consideration of magnetic resonance imaging, biopsy, and/or continued monitoring.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Cheng H.H.
        • Pritchard C.C.
        • Boyd T.
        • et al.
        Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
        Eur Urol. 2016; 69: 992-995
        • Pritchard C.C.
        • Mateo J.
        • Walsh M.F.
        • et al.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Loeb S.
        • Carter H.B.
        • Catalona W.J.
        • et al.
        Baseline prostate-specific antigen testing at a young age.
        Eur Urol. 2012; 61: 1-7
        • Na R.
        • Zheng S.L.
        • Han M.
        • et al.
        Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.
        Eur Urol. 2017; 71: 740-747
        • Annala M.
        • Struss W.J.
        • Warner E.W.
        • et al.
        Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer.
        Eur Urol. 2017; 72: 34-42
        • Bratt O.
        • Drevin L.
        • Akre O.
        • et al.
        Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study.
        J Natl Cancer Inst. 2016; 108
        • Hemminki K.
        • Ji J.
        • Forsti A.
        • et al.
        Concordance of survival in family members with prostate cancer.
        J Clin Oncol. 2008; 26: 1705-1709
        • Tang P.
        • Sun L.
        • Uhlman M.A.
        • et al.
        Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
        J Urol. 2010; 183: 946-950
        • Mucci L.A.
        • Hjelmborg J.B.
        • Harris J.R.
        • et al.
        Familial risk and heritability of cancer among twins in Nordic countries.
        JAMA. 2016; 315: 68-76
        • Vickers A.J.
        • Ulmert D.
        • Sjoberg D.D.
        • et al.
        Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
        BMJ. 2013; 346: f2023
        • Eeles R.
        • Goh C.
        • Castro E.
        • et al.
        The genetic epidemiology of prostate cancer and its clinical implications.
        Nat Rev Urol. 2014; 11: 18-31
        • Richards S.
        • Aziz N.
        • Bale S.
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
        Genet Med. 2015; 17: 405-424
        • Thompson D.
        • Easton D.F.
        • Breast Cancer Linkage Consortium
        Cancer incidence in BRCA1 mutation carriers.
        J Natl Cancer Inst. 2002; 94: 1358-1365
        • Leongamornlert D.
        • Mahmud N.
        • Tymrakiewicz M.
        • et al.
        Germline BRCA1 mutations increase prostate cancer risk.
        Br J Cancer. 2012; 106: 1697-1701
        • Breast Cancer Linkage Consortium
        Cancer risks in BRCA2 mutation carriers.
        J Natl Cancer Inst. 1999; 91: 1310-1316
        • Kote-Jarai Z.
        • Leongamornlert D.
        • Saunders E.
        • et al.
        BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
        Br J Cancer. 2011; 105: 1230-1234
        • Castro E.
        • Goh C.
        • Leongamornlert D.
        • et al.
        Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.
        Eur Urol. 2015; 68: 186-193
        • Castro E.
        • Goh C.
        • Olmos D.
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Gallagher D.J.
        • Gaudet M.M.
        • Pal P.
        • et al.
        Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
        Clin Cancer Res. 2010; 16: 2115-2121
        • Carter H.B.
        • Albertsen P.C.
        • Barry M.J.
        • et al.
        Early detection of prostate cancer: AUA Guideline.
        J Urol. 2013; 190: 419-426
        • Carroll P.R.
        • Parsons J.K.
        • Andriole G.
        • et al.
        NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
        J Natl Compr Canc Netw. 2016; 14: 509-519
        • Smith R.A.
        • Andrews K.
        • Brooks D.
        • et al.
        Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening.
        CA Cancer J Clin. 2016; 66: 96-114
      1. US Preventive Services Task Force (USPSTF), Screening for Prostate Cancer, Available at:, Accessed July 6, 2017.

        • Bancroft E.K.
        • Page E.C.
        • Castro E.
        • et al.
        Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
        Eur Urol. 2014; 66: 489-499
        • Oesterling J.E.
        • Jacobsen S.J.
        • Chute C.G.
        • et al.
        Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
        JAMA. 1993; 270: 860-864
        • Crawford E.D.
        Prostate Cancer Awareness Week: September 22 to 28, 1997.
        CA Cancer J Clin. 1997; 47: 288-296
        • Morgan T.O.
        • Jacobsen S.J.
        • McCarthy W.F.
        • et al.
        Age-specific reference ranges for serum prostate-specific antigen in black men.
        N Engl J Med. 1996; 335: 304-310
        • He D.
        • Wang M.
        • Chen X.
        • et al.
        Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population.
        Urology. 2004; 63: 722-726
        • Zhu H.
        • Roehl K.A.
        • Antenor J.A.
        • et al.
        Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
        Urology. 2005; 66: 547-551
        • Thompson I.M.
        • Pauler D.K.
        • Goodman P.J.
        • et al.
        Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
        N Engl J Med. 2004; 350: 2239-2246
        • Gulati R.
        • Cheng H.H.
        • Lange P.H.
        • et al.
        Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms.
        Cancer Epidemiol Biomarkers Prev. 2017; 26: 222-227
      2. National Comprehensive Cancer Network, Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2017), Available at:, Accessed July 6, 2017.

        • Gulati R.
        • Gore J.L.
        • Etzioni R.
        Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms.
        Ann Intern Med. 2013; 158: 145-153
        • Birnbaum J.K.
        • Feng Z.
        • Gulati R.
        • et al.
        Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 677-682
        • Kurian A.W.
        • Munoz D.F.
        • Rust P.
        • et al.
        Online tool to guide decisions for BRCA1/2 mutation carriers.
        J Clin Oncol. 2012; 30: 497-506